• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What are Clinical Trials?
    • Become a Clinical Trial Volunteer
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Clinilabs Boosts Phase I Capacity, Looks for More Growth

Clinilabs Boosts Phase I Capacity, Looks for More Growth

August 18, 2008
CenterWatch Staff

New York, N.Y.-based Clinilabs, a specialty contract research organization (CRO), has completed expansion of its phase I unit to 68 beds, including two new large observation rooms that can accommodate up to four beds each.

The company conducts phase I studies in any therapeutic area, including pharmacokinetic (PK), pharmacodynamic (PD), bioavailability (BA), bioequivalence (BE), drug interaction and food interaction studies.

Clinilabs also offers specialty services for complex PD studies, such as those that involve the collection of mood, cognition, psychomotor functioning, EEG, quantitative EEG, evoked potential and imaging data.

“Phase I studies are becoming increasingly complex, and sponsors depend on data from these studies to make crucial decisions about their development programs,” stated Dr. Gary Zammit, president and chief executive officer of Clinilabs.

Established seven years ago, Clinilabs has grown to 176 employees. “We started in 2001 with 12 beds and three PK chairs at our first facility in Manhattan, which was located in a remodeled, hospital-owned apartment building. This facility enabled us to take on small but complex studies, and set the stage for our continued focus on integrated PK/PD studies of a complex nature,” Zammit said.

Clinilabs is looking to expand its phase I work outside of New York but wants to be careful with that growth. “We anticipate the expansion of our facilities outside of NYC in the coming months, but we have not yet settled on the location. It is critical for a phase I site to be in an area where there is access to a pool of experienced and talented workers and where there is access to a wide diversity of study participants,” Zammit said.

    Upcoming Events

    • 05Dec

      Thriving in Clinical Research – Overcoming Common Challenges as a Site: Part 3 – Site Resourcing

    • 14Apr

      MAGI 2024: The Clinical Research Conference

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Jonathan Seltzer

      Thought Leadership: Remote Patient Monitoring Gives New View of Safety in Cardiac Clinical Trials

    • Quality_Compass-360x240.png

      Ask the Experts: Applying Quality by Design to Protocols

    • Obesity Treatment Patient

      Clinical Trials Need Greater Representation of Obese Patients, Experts Say

    • Modernize-360x240.png

      FDA IT Modernization Plan Prioritizes Data-Sharing, AI, Collaboration and More

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing